Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011)

* Preliminary observations in Non-Small Cell Lung Cancer ("NSCLC") support advancing to the registrational stage of the trial; anticipate full interim data set in 4Q'22 * Undifferentiated Pleomorphic Sarcoma ("UPS") and osteosarcoma will advance to Phase 2, part 2 enrollment, which is anticip...